API | visilizumab

visilizumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Visilizumab is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
visilizumab

More Chemistry

Pharmacology

Mechanisms of Action:
- T-cell surface glycoprotein CD3 epsilon chain (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

hum291 | nuvion | smart anti-cd3 | visilizumab

Organizations (9)

Research & Development (9)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Colitis, Ulcerative (Phase 3)

Crohn Disease (Phase 2)

Graft vs Host Disease (Phase 2)

Immunotherapy (Phase 3)

Intestinal Neoplasms (Phase 1)

Leukemia (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lymphoma (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 13
# of Trial Organizations: 9

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue